All News
Patients Don't Always Tell the Truth
Sometimes patients withhold information from their doctors, and a new study suggests that as much as 60 - 80% of patients consciously omit information to their doctors, despite knowing this may bear on their health and well-being.
Read Article
RheumNow Podcast – Can RA Be Prevented (12.7.18)
Dr. Jack Cush reviews the news and new journal articles from the past week on RheumNow.com:
Read Article
Chronic Kidney Disease Increasing in the U.S.A.
JAMA has published the Global Burden of Disease (GBD) study showing that that, from 2002 to 2016, the US burden of chronic kidney disease (CKD) increased, with some states exhibiting more than twice the burden as others.
Read Article
Deprescribing to Battle Polypharmacy
The Gerontological Society of America has published a report calling for deprescribing as a means of managing polypharmacy in the elderly.
Read Article
PRAIRI Study - Can RA Be Prevented?
B-cell depletion may offer a means of delaying the onset of clinical arthritis in adults at high risk, according to the PRAIRI study - a proof-of-mechanism study in pre-clinical RA patients.
Read Article
New ACR/NPF Guidelines for Management of Psoriatic Arthritis
The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues inclu
Read Article
Dendrimer Nanocarrier Delivers IGF-1 to Degenerative Cartilage
Researchers from MIT have developed a novel treatment for osteoarthritis (OA) by using dendrimer-based nanocarriers to deliver insulin-like growth factor 1 (IGF-1) to chondrocytes within joint cartilage and in animal models have shown when these nanocarriers injected into rat knees in models of O
Read Article
Limited Impact of Vitamin D Supplementation
A systematic review of 81 studies on vitamin D concludes that vitamin D supplementation does not prevent fractures or falls, or have clinically meaningful effects on bone mineral density.
Read Article
Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis
Another, new Janus kinase 1 (JAK1) inhibitor is out with impressive data - this time its filgotinib, demonstrating its efficacy and safety two separate clinical trials of patients with psoriatic arthritis or ankylosing spondylitis.
Read Article
RheumNow Podcast – To Needle or Not to Needle (11.30.18)
Dr. Jack Cush updates the news and reports from the past week at RheumNow.com:
Read Article
Rheumatoid Lung Disease Imposes Significant Morbidity and Mortality
Insurance claims data were analyzed for the frequency of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA) and finds that although rare, its frequency increased over time and it is associated with a significant mortality rate.
Read Article
Kallikrein Inhibitor Lanadelumab Prevents Hereditary Angioedema Attacks
Hereditary angioedema is a rare autosomal dominant disorder due to C1 inhibitor deficiency (type I) or dysfunction (type II) that leads to dysregulated plasma kallikrein activity, excess bradykinin production, and unpredictable potentially life-threatening recurrent angioedema attacks.
Read Article
Post-Approval Exploratory Trials with Pregabalin Often Fail
A systematic review of 238 pregabalin (Lyrica) trials for nonapproved indications shows that nearly two-thirds yielded uncertain evidence of efficacy, thereby questioning the off-label use or endorsement in clinical practice guidelines.
Read Article
FDA Approves Biosimilar Rituximab for NHL, not RA
The U.S. Food and Drug Administration on Wednesday approved Celltrion biosimilar of rituximab called Truxima; previously called CT-P10, now generically labeled as rituximab-abbs. This is the first biosimilar to the Rituxan currently approved to treat non-Hodgkin’s lymphoma. Truxima is not approved for use in rheumatoid arthritis, vasculitis, pemphigus vulgaris or chronic lymphocytic leukemia.
Read Article
Hepatic Safety of Urate Lowering Therapies in Gout
Lee and a group of Korean investigators have analyzed the comparative safety of allopurinol and febuxostat in a small cohort of gout patients with fatty liver disease (FLD) and found febuxostat had a lower risk for hepatotoxicity (defined as AST or ALT at least 3× the upper limit of normal)
Read Article
High CV Risk in Lupus
Patients with systemic lupus erythematosus (SLE) remain at risk for accelerated atherosclerosis, and important questions have yet to be answered, British investigators reported.
Read Article
Trazodone High Risk of Falls and Fractures
The CMAJ (Canadian Medical Association Journal) has reported that trazadone use in the elderly may be associated with a risk of falls and major fractures.
Read Article
Steroid Injection Superior to Splinting in Carpal Tunnel Syndrome
Lancet has published a comparative effectiveness study examining the the value of night splints (conservative treatment) vs local injection for patients with carpal tunnel syndrome.
Read Article
First FDA Approved Drug for HLH
The first drug specifically for primary hemophagocytic lymphohistiocytosis (HLH) was approved today, the FDA announced.
Read Article
Physical Activity Guidelines for Americans
The data are clear and disappointing: despite the well-known health benefits, four out of five US adults are not active physically. JAMA has published the new US Physical Activity Guidelines for Americans, so that health professionals and policy makers can promote lifestyle changes and awar
Read Article